WO2006094627A3 - Use of hydroxy tetrahydro-naphtalene derivates for the treatment of respiratory diseases - Google Patents

Use of hydroxy tetrahydro-naphtalene derivates for the treatment of respiratory diseases Download PDF

Info

Publication number
WO2006094627A3
WO2006094627A3 PCT/EP2006/001575 EP2006001575W WO2006094627A3 WO 2006094627 A3 WO2006094627 A3 WO 2006094627A3 EP 2006001575 W EP2006001575 W EP 2006001575W WO 2006094627 A3 WO2006094627 A3 WO 2006094627A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
bronchitis
rhinitis
pneumonia
respiratory diseases
Prior art date
Application number
PCT/EP2006/001575
Other languages
French (fr)
Other versions
WO2006094627A2 (en
Inventor
Cristina Alonso-Alija
Jang Gupta
Berthold Hinzen
Original Assignee
Bayer Healthcare Ag
Cristina Alonso-Alija
Jang Gupta
Berthold Hinzen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Cristina Alonso-Alija, Jang Gupta, Berthold Hinzen filed Critical Bayer Healthcare Ag
Priority to CA002599778A priority Critical patent/CA2599778A1/en
Priority to EP06707142A priority patent/EP1893189A2/en
Priority to JP2008500067A priority patent/JP2008532956A/en
Publication of WO2006094627A2 publication Critical patent/WO2006094627A2/en
Publication of WO2006094627A3 publication Critical patent/WO2006094627A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

This invention relates to new uses of hydroxy-tetrahydro-naphthalenylurea derivatives which are described in WO 03/095420 as an active ingredient of pharmaceutical preparations for the treatment of diseases associated with VR1 activity. The new uses of the present invention are the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of respiratory diseases or disorders such as the common cold, cough, sneeze, bronchitis including acute and chronic bronchitis, bronchiolitis, rhinitis, allergic rhinitis, vasomotor rhinitis, mucositis, sinusitis, allergy, disorders associated with exogenous irritants such as tobacco smoke, smog, high levels of atmospheric SO2 and noxious gases in the workplace, and airways hyperreactivity, milk product intolerance, Loffler's pneumonia, emphysema, cystic fibrosis, bronchiectasis, pulmonary fibrosis, pneumoconiosis, collagen vascular disease, granulomatous disease, laryngitis, pharyngitis, pneumonia, pleuritis, persistent asthma and chronic asthmatic bronchitis.
PCT/EP2006/001575 2005-03-05 2006-02-22 Use of hydroxy tetrahydro-naphtalene derivates for the treatment of respiratory diseases WO2006094627A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002599778A CA2599778A1 (en) 2005-03-05 2006-02-22 Use of hydroxy tetrahydro-naphtalene derivates for the treatment of respiratory diseases
EP06707142A EP1893189A2 (en) 2005-03-05 2006-02-22 Use of hydroxy tetrahydro-naphthalene derivatives for the treatment of respiratory diseases
JP2008500067A JP2008532956A (en) 2005-03-05 2006-02-22 Use of hydroxytetrahydro-naphthalene derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05004878.4 2005-03-05
EP05004878 2005-03-05

Publications (2)

Publication Number Publication Date
WO2006094627A2 WO2006094627A2 (en) 2006-09-14
WO2006094627A3 true WO2006094627A3 (en) 2006-12-07

Family

ID=36930668

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/001575 WO2006094627A2 (en) 2005-03-05 2006-02-22 Use of hydroxy tetrahydro-naphtalene derivates for the treatment of respiratory diseases

Country Status (4)

Country Link
EP (1) EP1893189A2 (en)
JP (1) JP2008532956A (en)
CA (1) CA2599778A1 (en)
WO (1) WO2006094627A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2672196A1 (en) 2006-12-20 2008-07-03 Abbott Laboratories Antagonists of the trpv1 receptor and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6605623B1 (en) * 1998-12-18 2003-08-12 Bristol-Myers Squibb Pharma Co. N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
WO2003095420A1 (en) * 2002-05-08 2003-11-20 Bayer Healthcare Ag Hydroxy tetrahydro-naphthalenylurea derivatives
WO2004052845A1 (en) * 2002-12-09 2004-06-24 Bayer Healthcare Ag Tetrahydro-naphthalene derivatives as vanilloid receptor antagonists
WO2004089877A1 (en) * 2003-04-14 2004-10-21 Astrazeneca Ab New hydroxynaphthyl amides
WO2004099177A1 (en) * 2003-05-09 2004-11-18 Merck Sharp & Dohme Limited Substituted-1-phthalazinamines as vr-1 antagonists
EP1493438A1 (en) * 2003-07-03 2005-01-05 Bayer HealthCare AG Vanilloid receptor (VR) inhibitors for treatment of Human Immunodeficiency Virus (HIV)-mediated pain states

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6605623B1 (en) * 1998-12-18 2003-08-12 Bristol-Myers Squibb Pharma Co. N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
WO2003095420A1 (en) * 2002-05-08 2003-11-20 Bayer Healthcare Ag Hydroxy tetrahydro-naphthalenylurea derivatives
WO2004052845A1 (en) * 2002-12-09 2004-06-24 Bayer Healthcare Ag Tetrahydro-naphthalene derivatives as vanilloid receptor antagonists
WO2004089877A1 (en) * 2003-04-14 2004-10-21 Astrazeneca Ab New hydroxynaphthyl amides
WO2004099177A1 (en) * 2003-05-09 2004-11-18 Merck Sharp & Dohme Limited Substituted-1-phthalazinamines as vr-1 antagonists
EP1493438A1 (en) * 2003-07-03 2005-01-05 Bayer HealthCare AG Vanilloid receptor (VR) inhibitors for treatment of Human Immunodeficiency Virus (HIV)-mediated pain states

Also Published As

Publication number Publication date
JP2008532956A (en) 2008-08-21
EP1893189A2 (en) 2008-03-05
CA2599778A1 (en) 2006-09-14
WO2006094627A2 (en) 2006-09-14

Similar Documents

Publication Publication Date Title
WO2005025540A3 (en) Mucoactive agents for treating a pulmonary disease
NO20072906L (en) Method of preventing or treating respiratory infections and acute otitis media in children
WO2000045834A3 (en) Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease
WO2006096434A3 (en) Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
WO2006108556A3 (en) Pharmaceutical aerosol composition
RS20050615A (en) Medicamentt comprising a highly long-lasting beta2-agonist in combination with other active ingredients
MXPA02011311A (en) Novel composition.
GEP20094781B (en) Sulfonamide derivatives for the treatment of diseases
WO2005120497A3 (en) Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
WO2006124609A3 (en) Methods and compositions for treating arg
WO2007082068A3 (en) Methods and compositions for treating asthma in human and non human primates
IL161290A0 (en) Stable composition comprising particles in a frozen aqueous matrix
Mengi et al. The effect of face mask usage on the allergic rhinitis symptoms in patients with pollen allergy during the covid-19 pandemic
MX2022012359A (en) Formulation.
WO2005011614A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease
WO2006083322A3 (en) Methods for the treatment and prevention of infection using anti-selectin agents
WO2003003997A3 (en) Use of hops or hop-malt extracts in cosmetic or dermatological preparations
WO2006094627A3 (en) Use of hydroxy tetrahydro-naphtalene derivates for the treatment of respiratory diseases
ATE361076T1 (en) COMBINATION OF LOTEPREDNOLETABONATE AND DFHO FOR THE TREATMENT OF RESPIRATORY DISEASES, ALLERGIC DISEASES, ASTHMA AND COPD
PH12018502521A1 (en) Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof
WO2004113286A3 (en) Mucin synthesis inhibitors
WO2005011602A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
EP1661892A4 (en) Condensed ring compound and use thereof
WO2007070509A3 (en) Epithelial sodium channel inhibiting agents and uses therefor
WO2004103364A3 (en) Treatment of respiratory disease by inhalation of synthetic matrix metalloprotease inhibitors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2006707142

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2599778

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008500067

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06707142

Country of ref document: EP

Kind code of ref document: A2

WWP Wipo information: published in national office

Ref document number: 2006707142

Country of ref document: EP